Surgery versus SABR for resectable non-small-cell lung cancer
2015; Elsevier BV; Volume: 16; Issue: 8 Linguagem: Inglês
10.1016/s1470-2045(15)00123-0
ISSN1474-5488
AutoresIsabelle Opitz, Gaetano Rocco, Alessandro Brunelli, Gonzálo Varela, Gilbert Massard, Walter Weder,
Tópico(s)Radiomics and Machine Learning in Medical Imaging
ResumoJoe Chang and colleagues 1 Chang JY Senan S Paul MA et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015; 16: 630-637 Summary Full Text Full Text PDF PubMed Scopus (1140) Google Scholar report the combined results of two randomised trials (STARS and ROSEL) comparing stereotactic ablative radiotherapy (SABR) with surgery for early-stage non-small-cell lung cancer. Both trials were halted early because of slow recruitment. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trialsSABR could be an option for treating operable stage I NSCLC. Because of the small patient sample size and short follow-up, additional randomised studies comparing SABR with surgery in operable patients are warranted. Full-Text PDF Surgery versus SABR for resectable non-small-cell lung cancer – Authors' replyWe appreciate the thoughtful comments of Christopher Cao, Lei Zhang, Masatsugu Hamaji, and Isabelle Opitz, Charles Dearman, and their colleagues. We recognise the limitations of our clinical trial, and these were extensively discussed in our Article.1 The strength of our analysis is that patients were prospectively accrued and randomised, thus eliminating the selection bias present in the retrospective series mentioned by the correspondents. Full-Text PDF
Referência(s)